

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chi-An Chiang, MD, PhD
 Protocol Project Manager: Chris Kippola
 Clinical Trial Program Manager: Laura Gildner, MS

Time/Location

Thursday, May 11, 2023 1:00 pm - 3:00 pm
 Room: Seacliff B-D (Bay Level)

Active Studies

S2101, "Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi. Activated: 10/14/22.

Agenda

- 1:00 – 1:20 PM Autoantibodies and Response to Therapy**
 Aaron Ring, MD, PhD
 Associate Professor of Immunobiology at Yale School of Medicine
- 1:20 – 2:00 PM IO Efforts in the NCTN Network: Current Status and Future Directions**
Current IO Efforts in Each Cooperative Group:
 SWOG: Katie Politi, Siwen Hu-Lieskovan
 ECOG/ACIRN: Ignacio Wistuba
 Alliance: Mark Klein, David Kozono
 NRG: Susanna Ulahannan
Panel Discussion: Future Directions and Collaborations:
 SWOG: Katie Politi, Siwen Hu-Lieskovan
 ECOG/ACIRN: Ignacio Wistuba
 Alliance: Mark Klein, David Kozono
 NRG: Susanna Ulahannan
- 2:00 – 2:15 PM How to Utilize SWOG Data for Immunotherapeutic Studies**
 Michael LeBlanc, PhD
 Group Statistician and Director of Statistical Center
- 2:15 – 2:20 PM Q & A**
- 2:20 – 3:00 PM S2101 iMATCH Pilot – Trial Updates, Site Coordinators Experience and Protocol 101**
 Katerina Politi, Siwen Hu-Lieskovan, Paul Swiecicki and iMATCH site coordinators